Association of Serum Mannose With Acute Respiratory Distress Syndrome Risk and Survival

Wei, Yongyue; Huang, Hui; Zhang, Ruyang; Zhu, Zhaozhong; Zhu, Ying; Lin, Lijuan; Dong, Xuesi; Wei, Liangmin; Chen, Xin; Z, Liu; Zhao, Yang; Li, Su; Chen, Feng; Christiani, David C.

doi:10.1001/jamanetworkopen.2020.34569

Cited by 9 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mortality of VAP was recorded to be 19.4–51.6% in China and 14 to 50% in other countries [ 9 , 10 ]. Critically ill patients are always admitted to the ICU and present high mortality risk [ 11 ]. VAP in ICU has an incidence of 13.5 to 23%, and accounts for one of the common causes of morbidity and mortality [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days

2021

View full text Add to dashboard Cite

Background Mechanical ventilation (MV) is often applied in critically ill patients in intensive care unit (ICU) to protect the airway from aspiration, and supplement more oxygen. MV may result in ventilator-associated pneumonia (VAP) in ICU patients. This study was to estimate the 90-day and 180-day mortalities of ICU patients with VAP, and to explore the influence of VAP on the outcomes of ICU patients. Methods Totally, 8182 patients who aged ≥18 years and received mechanical ventilation (MV) in ICU from Medical Information Mart for Intensive Care III (MIMIC III) database were involved in this study. All subjects were divided into the VAP group (n = 537) and the non-VAP group (n = 7626) based on the occurrence of VAP. Clinical data of all participants were collected. The effect of VAP on the prognosis of ICU patients was explored by binary logistic regression analysis. Results The results delineated that the 90-day mortality of VAP patients in ICU was 33.33% and 180-day mortality was 37.62%. The 90-day and 180-day mortality rates were higher in the VAP group than in the non-VAP group. After adjusting the confounders including age, ethnicity, heart failure, septicemia, simplified acute physiology score II (SAPSII) score, sequential organ failure assessment (SOFA) score, serum lactate, white blood cell (WBC), length of ICU stay, length of hospital stay, length of ventilation, antibiotic treatment, Pseudomonas aeruginosa (P.aeruginosa), methicillin-resistant Staphylococcus aureus (MRSA), other pathogens, the risk of 90-day and 180-day mortalities in VAP patients were 1.465 times (OR = 1.465, 95%CI: 1.188–1.807, P < 0.001) and 1.635 times (OR = 1.635, 95%CI: 1.333–2.005, P < 0.001) higher than those in non-VAP patients, respectively. Conclusions Our study revealed that ICU patients with VAP had poorer prognosis than those without VAP. The results of this study might offer a deeper insight into preventing the occurrence of VAP.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days

2021

View full text Add to dashboard Cite

show abstract

“…Given the contribution of MFN2 to pulmonary hemorrhage following lipopolysaccharide-induced lung injury in mice, GWAS data from the iSPAAR consortium ARDS study 34,35 were analyzed by SKAT 36 for possible complex associations between MFN2 SNPs and platelet count, ARDS risk, and prognosis. SKAT results indicated no statistical significance between MFN2 and platelet count ( P =0.8317) or ARDS risk ( P =0.8867).…”

Section: Resultsmentioning

confidence: 99%

Mitofusin-2 Regulates Platelet Mitochondria and Function

Jacob,

Kosaka,

Bhatlekar

et al. 2024

Circulation Research

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Single-nucleotide polymorphisms linked with the rs1474868 T allele (MFN2 [mitofusin-2] T/T) in the human mitochondrial fusion protein MFN2 gene are associated with reduced platelet MFN2 RNA expression and platelet counts. This study investigates the impact of MFN2 on megakaryocyte and platelet biology. METHODS: Mice with megakaryocyte/platelet deletion of Mfn2 ( Mfn2 −/− [Mfn2 conditional knockout]) were generated using Pf4-Cre crossed with floxed Mfn2 mice. Human megakaryocytes were generated from cord blood and platelets isolated from healthy subjects genotyped for rs1474868. Ex vivo approaches assessed mitochondrial morphology, function, and platelet activation responses. In vivo measurements included endogenous/transfused platelet life span, tail bleed time, transient middle cerebral artery occlusion, and pulmonary vascular permeability/hemorrhage following lipopolysaccharide-induced acute lung injury. RESULTS: Mitochondria was more fragmented in megakaryocytes derived from Mfn2 −/− mice and from human cord blood with MFN2 T/T genotype compared with control megakaryocytes. Human resting platelets of MFN2 T/T genotype had reduced MFN2 protein, diminished mitochondrial membrane potential, and an increased rate of phosphatidylserine exposure during ex vivo culture. Platelet counts and platelet life span were reduced in Mfn2 −/− mice accompanied by an increased rate of phosphatidylserine exposure in resting platelets, especially aged platelets, during ex vivo culture. Mfn2 −/− also decreased platelet mitochondrial membrane potential (basal) and activated mitochondrial oxygen consumption rate, reactive oxygen species generation, calcium flux, platelet-neutrophil aggregate formation, and phosphatidylserine exposure following dual agonist activation. Ultimately, Mfn2 −/− mice showed prolonged tail bleed times, decreased ischemic stroke infarct size after cerebral ischemia-reperfusion, and exacerbated pulmonary inflammatory hemorrhage following lipopolysaccharide-induced acute lung injury. Analysis of MFN2 SNPs in the iSPAAR study (Identification of SNPs Predisposing to Altered ALI Risk) identified a significant association between MFN2 and 28-day mortality in patients with acute respiratory distress syndrome. CONCLUSIONS: Mfn2 preserves mitochondrial phenotypes in megakaryocytes and platelets and influences platelet life span, function, and outcomes of stroke and lung injury.

show abstract

“…Recent research demonstrates that genetically regulated serum mannose is associated with ARDS risk and outcome, whereas increased serum mannose upon admission was associated with reduced ARDS risk and better survival rate [35]. Using mannose as a biomarker for sepsis patients could lead to prevention and clinical intervention in ARDS cases [35].…”

Section: Serum Mannose Biomarkersmentioning

confidence: 99%

Preventative Management of Sepsis-Induced Acute Respiratory Distress Syndrome in the Geriatric Population

Geyer-Roberts¹,

Lacatusu²,

Kester³

et al. 2023

Cureus

View full text Add to dashboard Cite

Sepsis and its treatment are the most common etiologies of acute respiratory distress syndrome (ARDS), which has a disturbing mortality rate. Sepsis management relies heavily on the introduction of resuscitative fluids. However, when fluids are paired with the circulating inflammatory mediators of sepsis, patients are prone to lung damage. Survivors of sepsis-induced ARDS become plagued with functional and/or psychological sequelae such as impaired memory, difficulty in concentrating, and decreased mental processing speed. Specific techniques can be implemented when diagnosing and treating elderly patients with sepsis to prevent the onset of ARDS, including bed elevation and early antibiotics. Additionally, albumin infusion may be beneficial; however, more research must be conducted. Finally, inflammatory mediators, including serum mannose biomarkers and extracellular histone therapy, show a promising avenue for future treatment. Although there is limited research on osteopathic manipulative medicine (OMT) on ARDS or sepsis-induced ARDS, OMT that focuses on alleviating rib and thoracic somatic dysfunctions has been used as an adjunct therapy to treat other respiratory diseases, such as pneumonia and chronic obstructive pulmonary disease (COPD). The results of these studies may garner interest in whether the use of OMT as an adjunct therapy may be beneficial for patients with ARDS or sepsis-induced ARDS. This paper is intended to review the current guidelines for sepsis and ARDS management in elderly patients to identify measures to prevent sepsis-induced ARDS.

show abstract

Association of Serum Mannose With Acute Respiratory Distress Syndrome Risk and Survival

Cited by 9 publications

References 43 publications

The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days

The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days

Mitofusin-2 Regulates Platelet Mitochondria and Function

Preventative Management of Sepsis-Induced Acute Respiratory Distress Syndrome in the Geriatric Population

Contact Info

Product

Resources

About